Close menu




October 20th, 2025 | 07:15 CEST

Almost 150% upside potential! Plug Power, Bayer, Planethic Group

  • Vegan
  • Food
  • Sustainability
  • Fuelcells
  • Pharma
  • bevtech
Photo credits: pixabay.com

Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? Analysts see over 100% upside potential. The recent correction appears exaggerated and could be an attractive entry point. The Company itself reports massive demand. Plug Power shares have performed strongly in recent months. Instead of taking profits, analysts see further upside — although some voices remain cautious, as the Company has promised to reach break-even many times before. And what do analysts say about Bayer? Very little at the moment. Goldman Sachs recommends the stock as a "Buy", but there is potential for a setback with the upcoming Q3 figures.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: PLUG POWER INC. DL-_01 | US72919P2020 , BAYER AG NA O.N. | DE000BAY0017 , PLANETHIC GROUP AG | DE000A3E5ED2

Table of contents:


    Planethic Group: Transformation offers over 100% upside potential

    Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? The stock was one of the turnaround stories of the first half of the year. Within a few months, it rose from EUR 5 to EUR 20. The correction since July came as no surprise, but its extent is surprising. However, at EUR 10.55, there is a great opportunity to buy or add to your position. In addition to the continued positive news flow, First Berlin has started coverage and the verdict is clear: "Buy", with a price target of EUR 26.

    Analysts see good reasons for the nearly 150% upside potential: The Berlin-based company is positioning itself this year as a "BevTech" pioneer with its proprietary 2D printing technology for dried, sliced, and packaged beverages. Initially, the Mililk® brand—a long-life, dried oat milk—is to be launched on the US market. Distribution agreements are already in place with Jindilli Beverages, a supplier to major chains such as Starbucks and McDonald's. If the ramp-up is successful, First Berlin expects Planethic to gain market share in the billion-dollar non-dairy category thanks to cost advantages and its sustainability profile. For 2027, analysts forecast an increase in revenue to EUR 117 million (2024: EUR 10.8 million) and an EBITDA margin of around 11%. Earnings per share are then expected to reach EUR 0.50 to the study.

    https://youtu.be/BSqBRGIHUm0?si=PjjG2CaJxMliDD4Y

    The estimates may even be too conservative. In its latest press release on its cooperation with the US group Vitiprints, Planethic emphasized that global demand for Mililk® is growing strongly and now exceeds 400 million liters per year. This means that the sales potential is likely to be well over EUR 200 million, especially since printed oat milk is only the beginning. The range is to be expanded to include other milk alternatives and juices.

    Plug Power: Another 50% increase in share price?

    Plug Power's share price is actually ripe for a correction. It has more than tripled in value within six months and is once again worth more than USD 4 billion on the stock market. However, the share price has remained stable so far, trading above USD 3. Even two surprises did not cause a sustained slide in the share price. Both the capital measure and the departure of the CEO had the potential to do so.

    According to analysts at TD Cowen, there is even more to come for Plug shares. After talks with management, the "Buy" recommendation was confirmed, and the price target was raised from USD 3 to USD 4.50. Management plausibly explained its plans for reaching profitability. Among other things, cost reductions, scaling, and price adjustments are expected to contribute to this. Plug Power sees short-term growth potential, particularly in the areas of electrolysers and material handling systems.

    However, the hydrogen pioneer is currently still burning through millions. It has therefore taken advantage of the share price increase and recently secured around USD 370 million in fresh capital through a warrant transaction.

    Not everyone sees Plug Power's future as so rosy. For example, Clear Street believes the Company still has a long way to go before it breaks even. Analysts consider the share price of USD 3.50 to be fairly valued and recently adjusted their recommendation from "Buy" to "Hold."

    Bayer: Analysts cautious

    And what do analysts say about Bayer shares? The Leverkusen-based company's shares have gained 38% in the current year, twice as much as the DAX.

    However, there have been remarkably few analyst comments in recent weeks. Goldman Sachs was the last to comment, slightly reducing its price target from EUR 35 to EUR 34.50. However, this was based solely on exchange rate changes. It is noteworthy that the analysts noted that their estimates for Bayer's third quarter are well below average expectations. EBITDA is 11% lower, and earnings per share are as much as 45% lower. If Goldman is right, there could be numerous negative comments when Bayer reports on the third quarter in November—an exact date has not yet been set.

    Overall, analysts are currently somewhat cautious about Bayer. According to marketscreener.com, 12 out of 19 analysts rate the pharmaceutical and agricultural group's stock as "Hold", seven experts recommend buying, with the average price target being EUR 28.50. Bayer shares are currently trading at EUR 26.80.


    The repositioning at Planethic Group is bearing fruit and should soon have a noticeable impact on sales and profits. In any case, the potential appears enormous, and analysts are also convinced. Plug Power appears to be winning back investors and analysts. However, there is still a long way to go before it breaks even. Bayer has already performed well. Buying the stock does not seem compelling at the moment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on April 2nd, 2026 | 09:50 CEST

    Oil Price Shock as an Opportunity: 100% Potential with Nel ASA, A.H.T. Syngas, and Plug Power

    • syngas
    • biochar
    • Sustainability
    • renewableenergy
    • Hydrogen

    Daily updates continue to emerge on efforts to rein in Iran. President Donald Trump claims to have already achieved all war objectives. Yet, the Iranians appear surprisingly self-confident for a nation portrayed as defeated, pushing back against the media narrative surrounding their willingness to negotiate. Meanwhile, the German government has introduced a new fuel pricing law. Since April 1, a package of measures aimed at curbing price increases has come into effect. In the future, price increases will only be permitted once per day at 12:00 noon, while price reductions remain possible at any time. The law was drafted based on common practice in Austria and is intended to provide greater transparency and stability. However, the initial effect was mixed: although the Brent spot price fell by 7% at midday and the euro weakened against the US dollar, fuel prices did not decline accordingly.

    Read

    Commented by Nico Popp on March 31st, 2026 | 08:20 CEST

    Dividends as Portfolio Anchors: Familiar Names Sanofi and BB Biotech – Hidden Gem RE Royalties

    • royalties
    • dividends
    • Biotech
    • Pharma
    • Sustainability
    • renewableenergy

    In a market environment marked by structural upheaval, portfolio stability is increasingly coming into focus. Analysts at JPMorgan emphasize that preserving accumulated gains requires a renewed focus on resilience and diversification. Research by S&P Global also shows that dividends have contributed over 50% to the total return of global equities over the past 25 years. Choosing the right stocks is crucial to securing steady cash flows even during volatile market phases. Pharmaceutical giant Sanofi, investment firm BB Biotech, and the virtually unknown Canadian company RE Royalties offer fundamentally different but extremely promising approaches for investors.

    Read

    Commented by Nico Popp on March 30th, 2026 | 08:30 CEST

    A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations
    • Cancer

    Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.

    Read